These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Reinelt H; Radermacher P; Kiefer P; Fischer G; Wachter U; Vogt J; Georgieff M Crit Care Med; 1999 Feb; 27(2):325-31. PubMed ID: 10075057 [TBL] [Abstract][Full Text] [Related]
11. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278 [TBL] [Abstract][Full Text] [Related]
12. Studies on the mechanism of action of the hypotensive effect of ketanserin. Marwood JF; Stokes GS Clin Exp Pharmacol Physiol; 1984; 11(2):125-32. PubMed ID: 6086191 [TBL] [Abstract][Full Text] [Related]
13. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension. Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863 [TBL] [Abstract][Full Text] [Related]
14. Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. Sonnenberg GE; Keller U; Perruchoud A; Burckhardt D; Gyr K Gastroenterology; 1981 Mar; 80(3):526-32. PubMed ID: 6108898 [TBL] [Abstract][Full Text] [Related]
15. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. Hadengue A; Lee SS; Moreau R; Braillon A; Lebrec D Hepatology; 1987; 7(4):644-7. PubMed ID: 3610044 [TBL] [Abstract][Full Text] [Related]
16. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. Hadengue A; Moreau R; Cerini R; Koshy A; Lee SS; Lebrec D Hepatology; 1989 Jan; 9(1):83-7. PubMed ID: 2908872 [TBL] [Abstract][Full Text] [Related]
17. Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin. McCall RB; Schuette MR J Pharmacol Exp Ther; 1984 Mar; 228(3):704-10. PubMed ID: 6323678 [TBL] [Abstract][Full Text] [Related]
18. Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep. Nelson M; Coghlan JP; Denton DA; Tresham JJ; Whitworth JA; Scoggins BA Clin Exp Pharmacol Physiol; 1987 Jul; 14(7):555-63. PubMed ID: 3124998 [TBL] [Abstract][Full Text] [Related]
19. Ketanserin: a possible tool for studying the role of serotonin in hypertension. Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035 [TBL] [Abstract][Full Text] [Related]
20. Effect of calcium antagonists on basal and digitalis-dependent changes in splanchnic and systemic hemodynamics. Gasić S; Eichler HG; Korn A Clin Pharmacol Ther; 1987 Apr; 41(4):460-6. PubMed ID: 3829582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]